Cargando…
Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress
Immune checkpoint inhibitor-associated adverse reactions (irAEs) are a clinical treatment issue that requires additional attention when ICIs have significant survival benefits in patients with advanced hepatocellular carcinoma (HCC). Among them, ICIs-associated myocarditis (ICIAM) is a kind of sever...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458972/ https://www.ncbi.nlm.nih.gov/pubmed/36091070 http://dx.doi.org/10.3389/fimmu.2022.995121 |
_version_ | 1784786398152228864 |
---|---|
author | Ji, Hongxiang Wen, Zhijian Liu, Bin Chen, Hongbiao Lin, Qian Chen, Zhan |
author_facet | Ji, Hongxiang Wen, Zhijian Liu, Bin Chen, Hongbiao Lin, Qian Chen, Zhan |
author_sort | Ji, Hongxiang |
collection | PubMed |
description | Immune checkpoint inhibitor-associated adverse reactions (irAEs) are a clinical treatment issue that requires additional attention when ICIs have significant survival benefits in patients with advanced hepatocellular carcinoma (HCC). Among them, ICIs-associated myocarditis (ICIAM) is a kind of severe irAE with a high mortality rate (17%–50%). Despite its low incidence (PD1/PD-L1 related: 0.41%–0.8%), ICIAM can significantly disturb the decision making of therapeutic schemes and even the survival outcomes of patients. ICIAM induced by sintilimab has not been reported in any complete clinical studies yet and understanding the clinical characteristics involved may inform better practices for the management. Here, we reported a 78 y/o patient with advanced HCC, who experienced ICIAM induced by sintilimab within a short course from treatment onset and found that adequate baseline examination before the implementation of the therapeutic scheme, regular monitoring of myocardial enzymonram and cardiac imaging were measures for the early detection, while glucocorticoid pulse therapy is still the best choice with timely and sufficient application. Simultaneously, the combination of other immunosuppressants may lead to better results. New-predictive markers and examination methods are still required to facilitate the early detection. |
format | Online Article Text |
id | pubmed-9458972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94589722022-09-10 Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress Ji, Hongxiang Wen, Zhijian Liu, Bin Chen, Hongbiao Lin, Qian Chen, Zhan Front Immunol Immunology Immune checkpoint inhibitor-associated adverse reactions (irAEs) are a clinical treatment issue that requires additional attention when ICIs have significant survival benefits in patients with advanced hepatocellular carcinoma (HCC). Among them, ICIs-associated myocarditis (ICIAM) is a kind of severe irAE with a high mortality rate (17%–50%). Despite its low incidence (PD1/PD-L1 related: 0.41%–0.8%), ICIAM can significantly disturb the decision making of therapeutic schemes and even the survival outcomes of patients. ICIAM induced by sintilimab has not been reported in any complete clinical studies yet and understanding the clinical characteristics involved may inform better practices for the management. Here, we reported a 78 y/o patient with advanced HCC, who experienced ICIAM induced by sintilimab within a short course from treatment onset and found that adequate baseline examination before the implementation of the therapeutic scheme, regular monitoring of myocardial enzymonram and cardiac imaging were measures for the early detection, while glucocorticoid pulse therapy is still the best choice with timely and sufficient application. Simultaneously, the combination of other immunosuppressants may lead to better results. New-predictive markers and examination methods are still required to facilitate the early detection. Frontiers Media S.A. 2022-08-26 /pmc/articles/PMC9458972/ /pubmed/36091070 http://dx.doi.org/10.3389/fimmu.2022.995121 Text en Copyright © 2022 Ji, Wen, Liu, Chen, Lin and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Ji, Hongxiang Wen, Zhijian Liu, Bin Chen, Hongbiao Lin, Qian Chen, Zhan Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress |
title | Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress |
title_full | Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress |
title_fullStr | Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress |
title_full_unstemmed | Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress |
title_short | Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress |
title_sort | sintilimab induced iciam in the treatment of advanced hcc: a case report and analysis of research progress |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458972/ https://www.ncbi.nlm.nih.gov/pubmed/36091070 http://dx.doi.org/10.3389/fimmu.2022.995121 |
work_keys_str_mv | AT jihongxiang sintilimabinducediciaminthetreatmentofadvancedhccacasereportandanalysisofresearchprogress AT wenzhijian sintilimabinducediciaminthetreatmentofadvancedhccacasereportandanalysisofresearchprogress AT liubin sintilimabinducediciaminthetreatmentofadvancedhccacasereportandanalysisofresearchprogress AT chenhongbiao sintilimabinducediciaminthetreatmentofadvancedhccacasereportandanalysisofresearchprogress AT linqian sintilimabinducediciaminthetreatmentofadvancedhccacasereportandanalysisofresearchprogress AT chenzhan sintilimabinducediciaminthetreatmentofadvancedhccacasereportandanalysisofresearchprogress |